Institutional framework for integrated Pharmaceutical Benefits Management: results from a systematic review

Hermanowski, Tomasz; Drozdowska, Aleksandra; Kowalczyk, Marta

doi:10.5334/ijic.2253

Cited by 2 publications

(2 citation statements)

References 11 publications

(13 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is quite common to make the initial search very broad to avoid the possibility of omitting any relevant studies, but the final number of studies satisfying inclusion criteria is typically much smaller than the initial search identified. [ 6 , 15 – 16 ]…”

Section: Resultsmentioning

confidence: 99%

Quality of pharmacoeconomic research in China

Jian

et al. 2016

Medicine

View full text Add to dashboard Cite

Background:The number of pharmacoeconomic publications in the literature from China has risen rapidly, but the quality of pharmacoeconomic publications from China has not been analyzed.Objectives:This study aims to identify all recent pharmacoeconomic publications from China, to critically appraise the reporting quality, and to summarize the results.Methods:Four databases (PubMed, Web of Science, Medline, and EmBase) were searched for original articles published up to December 31, 2014. The Consolidated Health Economic Evaluation Reporting Standards statement including 24 items was used to assess the quality of reporting of these articles.Results:Of 1046 articles identified, 32 studies fulfilled the inclusion criteria. They were published in 23 different journals. Quality of reporting varied between studies, with an average score of 18.7 (SD = 4.33) out of 24 (range 9–23.5). There was an increasing trend of pharmacoeconomic publications and reporting quality over years from 2003 to 2014. According to the Consolidated Health Economic Evaluation Reporting Standards, the reporting quality for the items including “title,” “comparators of method,” and “measurement of effectiveness” are quite low, with less than 50% of studies fully satisfying these reporting standards. In contrast, reporting was good for the items including “introduction,” “study perspective,” “choice of health outcomes,” “study parameters,” “characterizing heterogeneity,” and “discussion,” with more than 75% of the articles satisfying these reporting criteria. The remaining items fell in between these 2 extremes, with 50% to 75% of studies satisfying these criteria.Conclusion:Our study suggests the need for improvement in a number of reporting criteria. But the criteria for which reporting quality was low seem to be limitations that would be straightforward to correct in future studies.

show abstract

Section: Resultsmentioning

confidence: 99%

Quality of pharmacoeconomic research in China

Jian

et al. 2016

Medicine

View full text Add to dashboard Cite

show abstract

“…Медианы фактических затрат в исследуемых субъектах РФ (10-й и 90-й процентили) составили 1723,0 руб. ( [3,[7][8][9]. Вместе с тем, в зарубежных странах механизмы реализации программ ЛЛО имеет свои специфические особенности и отличия.…”

Section: материалы и методыunclassified

Analysis of the Implementation of the Federal Assurance Program of Supporting Beneficiaries With Indispensable Medicinal Preparations in the Subjects of the Russian Federation

Петрухина

Yagudina

Ryazanova

et al. 2021

Farm. farmakol. (Pâtigorsk)

View full text Add to dashboard Cite

The aim of the research was to study the main indicative indicators of the implementation of The Federal Program “Provision of Essential Medicines” in 20 constituent entities of the Russian Federation based on the results of 2018 and 2019.Materials and methods. The analyzed data were provided on the basis of the request cards specially designed by the health authorities of 20 subjects of the Russian Federation located in seven federal districts.Results. It has been established that the funds allocated to the constituent entities of the Russian Federation, directly depend on the number of beneficiaries who retained the right to receive state social assistance in the form of a set of social services. These funds also correlate with the indicator “Population of the subject of the Russian Federation”. In all the studied constituent entities of the Russian Federation, more than 50% of the total number of people who retained the right to preferential drug provision in 2018–2019, asked for medical help as part of the program “Provision of Essential Medicines”. Herein, in the constituent entities of the Russian Federation, the average cost of one prescription amounted to 1,107.2 rubles in 2018 and 1,297.2 rubles in 2019. The estimated indicator “The average actual expenditures per 1 citizen entitled to state social assistance in the form of a set of social services, amounted to 1,723.0±90.2 rubles in 2018 and 1,526.8±80.5 rubles in 2019, which is higher than the approved input normative (823.3 rubles and 861.8 rubles in 2018 and 2019, respectively).Conclusion. Thus, an excess of average actual expenditures per citizen entitled to state social assistance in the form of a set of social services, was notified over the standards established by the decrees of the Government of the Russian Federation. The revealed discrepancy between the normative and actual expenditures can also be an indirect confirmation of the fact that the most needy beneficiaries with chronic diseases remained in the program “Provision of Essential Medicines”.

show abstract

Institutional framework for integrated Pharmaceutical Benefits Management: results from a systematic review

Cited by 2 publications

References 11 publications

Quality of pharmacoeconomic research in China

Quality of pharmacoeconomic research in China

Analysis of the Implementation of the Federal Assurance Program of Supporting Beneficiaries With Indispensable Medicinal Preparations in the Subjects of the Russian Federation

Contact Info

Product

Resources

About